Nutrients, Microglia Aging, and Brain Aging

Oxidative Medicine and Cellular Longevity

Volumn 2016, Issue , 2016, Pages

  Wu, Zhou ^a   Yu, Janchun ^b   Zhu, Aiqin ^c   Nakanishi, Hiroshi ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^c Institution of Geriatric Qinghai Provincial Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

NEURODEGENERATIVE DISEASES; NUTRIENTS;

ALZHEIMER'S DISEASE; ANTIOXIDANT NUTRIENT; CELLULAR ACTIVATION; INFLAMMATORY MEDIATORS; LEARNING AND MEMORY; LIFE EXPECTANCIES; REACTIVE OXYGEN SPECIES; SYSTEMIC INFLAMMATION;

PATHOLOGY;

ANTIOXIDANT; ASCORBIC ACID; PROPOLIS; REACTIVE OXYGEN METABOLITE;

AGING; ALZHEIMER DISEASE; BRAIN; COGNITION; DNA DAMAGE; HUMAN; MICROGLIA; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; NUTRIENT; REVIEW; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; CELL AGING; FOOD; INFLAMMATION; OXIDATIVE STRESS; PATHOLOGY;

AGING; ANIMALS; BRAIN; CELL AGING; FOOD; HUMANS; INFLAMMATION; MICROGLIA; OXIDATIVE STRESS;

EID: 84959431403     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2016/7498528     Document Type: Review

References (119)

1. H. Nakanishi and Z. Wu, "Microglia-aging: roles of microglial lysosome-and mitochondria-derived reactive oxygen species in brain aging," Behavioural Brain Research, vol. 201, no. 1, pp. 1-7, 2009.
2. C. Kaur and E. A. Ling, "Periventricular white matter damage in the hypoxic neonatal brain: role of microglial cells," Progress in Neurobiology, vol. 87, no. 4, pp. 264-280, 2009.
3. C. Kaur, V. Sivakumar, G. W. Yip, and E. A. Ling, "Expression of syndecan-2 in the amoeboid microglial cells and its involvement in inflammation in the hypoxic developing brain," GLIA, vol. 57, no. 3, pp. 336-349, 2009.
4. G. Rathnasamy, E.-A. Ling, and C. Kaur, "Iron and iron regulatory proteins in amoeboid microglial cells are linked to oligodendrocyte death in hypoxic neonatal rat periventricular whitematter through production of proinflammatory cytokines and reactive oxygen/nitrogen species," The Journal of Neuroscience, vol. 31, no. 49, pp. 17982-17995, 2011.
5. L. Yao, E. M. Kan, J. Lu et al., "Toll-like receptor 4 mediates microglial activation and production of inflammatory mediators in neonatal rat brain following hypoxia: Role of TLR4 in hypoxic microglia," Journal of Neuroinflammation, vol. 10, article 23, 2013.
6. C. Kaur, V. Sivakumar, Z. Zou, and E.-A. Ling, "Microgliaderived proinflammatory cytokines tumor necrosis factor- and interleukin-1 induce Purkinje neuronal apoptosis via their receptors in hypoxic neonatal rat brain," Brain Structure and Function, vol. 219, no. 1, pp. 151-170, 2014.
7. F. Fabbri, S. Carloni, G. Brigliadori, W. Zoli, R. Lapalombella, and M. Marini, "Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: A cytometric study," BMC Cell Biology, vol. 7, article 6, 2006.
8. S. Carloni, E. Mazzoni, M. Cimino et al., "Simvastatin reduces caspase-3 activation and inflammatory markers induced by hypoxia-ischemia in the newborn rat," Neurobiology of Disease, vol. 21, no. 1, pp. 119-126, 2006.
9. Y. Deng, J. Lu, V. Sivakumar, E. A. Ling, andC. Kaur, "Amoeboid microglia in the periventricular white matter induce oligodendrocyte damage through expression of proinflammatory cytokines via MAP kinase signaling pathway in hypoxic neonatal rats," Brain Pathology, vol. 18, no. 3, pp. 387-400, 2008.
10. V. Sivakumar,W. S. Foulds, C. D. Luu, E.-A. Ling, and C. Kaur, "Retinal ganglion cell death is induced by microglia derived pro-inflammatory cytokines in the hypoxic neonatal retina," The Journal of Pathology, vol. 224, no. 2, pp. 245-260, 2011.
11. Z. Wu, A. Zhu, F. Takayama et al., "Brazilian green propolis suppresses the hypoxia-induced neuroinflammatory responses by inhibiting NF-B activation in microglia," Oxidative Medicine and Cellular Longevity, vol. 2013, Article ID 906726, 10 pages, 2013.
12. E. G. McGeer and P. L. McGeer, "Inflammatory processes in Alzheimer's disease," Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 5, pp. 741-749, 2003.
13. M. Yamamoto, T. Kiyota, M. Horiba et al., "Interferon- and tumor necrosis factor- regulate amyloid- plaque deposition and -secretase expression in Swedish mutant APP transgenic mice," The American Journal of Pathology, vol. 170, no. 2, pp. 680-692, 2007.
14. Y.-F. Liaoi, B.-J. Wang, H.-T. Cheng,L.-H. Kuo, andM. S. Wolfe, "Tumor necrosis factor-, interleukin-1, and interferon- stimulate -secretase-mediated cleavage of amyloid precursor protein through a JNK-dependentMAPKpathway,"TheJournal of Biological Chemistry, vol. 279, no. 47, pp. 49523-49532, 2004.
15. ADAPT Research Group, C. L. Meinert, L. D. McCaffrey, and J. C. Breitner, "Alzheimer's disease anti-inflammatory prevention trial: design, methods, and baseline results," Alzheimer's & Dementia, vol. 5, no. 2, pp. 93-104, 2009.
16. W. J. Lukiw and N. G. Bazan, "Neuroinflammatory signaling upregulation in Alzheimer's disease," Neurochemical Research, vol. 25, no. 9-10, pp. 1173-1184, 2000.
17. V. H. Perry, T. A. Newman, and C. Cunningham, "The impact of systemic infection on the progression of neurodegenerative disease," Nature Reviews Neuroscience, vol. 4, no. 2, pp. 103-112, 2003.
18. V. H. Perry, "The influence of systemic inflammation on inflammation in the brain: implications for chronic neurodegenerative disease," Brain, Behavior, and Immunity, vol. 18, no. 5, pp. 407-413, 2004.
19. N. Pischon, N. Heng, J.-P. Bernimoulin, B.-M. Kleber, S. N. Willich, and T. Pischon, "Obesity, inflammation, and periodontal disease," Journal of Dental Research, vol. 86, no. 5, pp. 400-409, 2007.
20. Z. Wu and H. Nakanishi, "Connection between periodontitis and Alzheimer's disease: possible roles of microglia and leptomeningeal cells," Journal of Pharmacological Sciences, vol. 126, no. 1, pp. 8-13, 2014.
21. A.-Q. Zhu, Y.-D. Chu, Q.-X. Li, and C. L. Masters, "Tibetmedicine effects on -amyloid pathology in a transgenic mouse model of Alzheimer's disease," Chinese Pharmacological Bulletin, vol. 25, no. 6, pp. 720-724, 2009.
22. P. L. Mcgeer, E. Mcgeer, J. Rogers, and J. Sibley, "Antiinflammatory drugs and Alzheimer disease," The Lancet, vol. 335, no. 8696, p. 1037, 1990.
23. P. L. McGeer, M. Schulzer, and E. G. McGeer, "Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: A review of 17 epidemiologic studies," Neurology, vol. 47, no. 2, pp. 425-432, 1996.
24. B. A. In't Veld, A. Ruitenberg, A. Hofman et al., "Nonsteroidal anti-inflammatory drugs and the risk of Alzheimer's disease," The New England Journal of Medicine, vol. 345, no. 21, pp. 1515-1521, 2001.
25. C. A. Szekely, J. E. Thorne, P. P. Zandi et al., "Nonsteroidal antiinflammatory drugs for the prevention of Alzheimer's disease: A systematic review," Neuroepidemiology, vol. 23, no. 4, pp. 159-169, 2004.
26. K. Wallin, A. Solomon, I. Kareholt, J. Tuomilehto, H. Soininen, and K. Walin, "Midlife rheumatoid arthritis increases the risk of cognitive impairment two decades later: A population-based study," Journal of Alzheimer's Disease, vol. 31, no. 3, pp. 669-676, 2012.
27. J. M. Noble, L. N. Borrell, P. N. Papapanou, M. S. V. Elkind, N. Scarmeas, and C. B. Wright, "Periodontitis is associated with cognitive impairment among older adults: Analysis of NHANES-III," Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 11, pp. 1206-1211, 2009.
28. P. S. Stein, M. J. Steffen, C. Smith et al., "Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease," Alzheimer's and Dementia, vol. 8, no. 3, pp. 196-203, 2012.
29. S. Poole, S. K. Singhrao, L. Kesavalu, M. A. Curtis, and S. Crean, "Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue," Journal of Alzheimer's Disease, vol. 36, no. 4, pp. 665-677, 2013.
30. G. Riviere, K. H. Riviere, and K. S. Smith, "Molecular and immunological evidence of oral Treponema in the human brain and their association with Alzheimer's disease," Oral Microbiology and Immunology, vol. 17, no. 2, pp. 113-118, 2002.
31. M. D. Neal, C. Leaphart, R. Levy et al., "Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier,"The Journal of Immunology, vol. 176, no. 5, pp. 3070-3079, 2006.
32. R. Zhang, R. G. Miller, R. Gascon et al., "Circulating endotoxin and systemic immune activation in sporadic amyotrophic lateral sclerosis (sALS)," Journal of Neuroimmunology, vol. 206, no. 1-2, pp. 121-124, 2009.
33. R. Zhang, R. G. Miller, C. Madison et al., "Systemic immune system alterations in early stages of Alzheimer's disease," Journal of Neuroimmunology, vol. 256, no. 1-2, pp. 38-42, 2013.
34. J. R. Hall, A. R. Wiechmann, L. A. Johnson et al., "Biomarkers of vascular risk, systemic inflammation, and microvascular pathology and neuropsychiatric symptoms in Alzheimer's disease," Journal of Alzheimer's Disease, vol. 35, no. 2, pp. 363-371, 2013.
35. M. J. Engelhart, M. I. Geerlings, J. Meijer et al., "Inflammatory proteins in plasma and the risk of dementia: the rotterdam study," Archives of Neurology, vol. 61, no. 5, pp. 668-672, 2004.
36. D. Krstic, A. Madhusudan, J. Doehner et al., "Systemic immune challenges trigger and drive Alzheimer-like neuropathology in mice," Journal of Neuroinflammation, vol. 9, article 151, 2012.
37. J. J. M. Hoozemans, A. J. M. Rozemuller, E. S. van Haastert, P. Eikelenboom, and W. A. van Gool, "Neuroinflammation in Alzheimer's disease wanes with age," Journal of Neuroinflammation, vol. 8, article 171, 2011.
38. P. Eikelenboom, E. Van Exel, J. J. M. Hoozemans, R. Veerhuis,A. J. M. Rozemuller, and W. A. Van Gool, "Neuroinflammation- an early event in both the history and pathogenesis of Alzheimer's disease," Neurodegenerative Diseases, vol. 7, no. 1-3, pp. 38-41, 2010.
39. P. Eikelenboom, J. J. M. Hoozemans, R. Veerhuis, E. Van Exel, A. J. M. Rozemuller, andW. A. Van Gool, "Whether, when and how chronic inflammation increases the risk of developing lateonset Alzheimer's disease," Alzheimer's Research &Therapy, vol. 4, no. 3, article no. 15, 2012.
40. V. Afonso, R. Champy, D. Mitrovic, P. Collin, and A. Lomri, "Reactive oxygen species and superoxide dismutases: role in joint diseases," Joint Bone Spine, vol. 74, no. 4, pp. 324-329, 2007.
41. V. Afonso, G. Santos, P. Collin et al., "Tumor necrosis factoralpha down-regulates human Cu/Zn superoxide dismutase 1 promoter via JNK/AP-1 signaling pathway," Free Radical Biology and Medicine, vol. 41, no. 5, pp. 709-721, 2006.
42. P. Strlin and S. L. Marklund, "Multiple cytokines regulate the expression of extracellular superoxide dismutase in human vascular smoothmuscle cells," Atherosclerosis, vol. 151, no. 2, pp. 433-441, 2000.
43. C. C. Tsai, H. S. Chen, S. L. Chen et al., "Lipid peroxidation: A possible role in the induction and progression of chronic periodontitis," Journal of Periodontal Research, vol. 40, no. 5, pp. 378-384, 2005.
44. T. Konopka, K. Król, W. Kopec, and H. Gerber, "Total antioxidant status and 8-hydroxy-2-deoxyguanosine levels in gingival and peripheral blood of periodontitis patients," Archivum Immunologiae et Therapiae Experimentalis, vol. 55, no. 6, pp. 417-422, 2007.
45. T. Yamamoto, T. Tomofuji,N. Tamaki, D. Ekuni, T. Azuma, and T. Sanbe, "Effects of topical application of lipopolysaccharide and proteases on hepatic injury induced by high-cholesterol diet in rats," Journal of Periodontal Research, vol. 45, no. 1, pp. 129-135, 2010.
46. F. D'Aiuto, L. Nibali, M. Parkar, K. Patel, J. Suvan, and N. Donos, "Oxidative stress, systemic inflammation, and severe periodontitis," Journal of Dental Research, vol. 89, no. 11, pp. 1241-1246, 2010.
47. M. Almeida, L. Han, M. Martin-Millan, C. A. O'Brien, and S. C. Manolagas, "Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting -catenin from T cell factor-to forkhead box O-mediated transcription," The Journal of Biological Chemistry, vol. 282, no. 37, pp. 27298-27305, 2007.
48. X.-C. Bai,D. Lu, J. Bai et al., "Oxidative stress inhibits osteoblastic differentiation of bone cells by ERK and NF-B," Biochemical and Biophysical Research Communications, vol. 314, no. 1, pp. 197-207, 2004.
49. N. Mody, F. Parhami, T. A. Sarafian, andL. L. Demer, "Oxidative stress modulates osteoblastic differentiation of vascular and bone cells," Free Radical Biology andMedicine, vol. 31, no. 4, pp. 509-519, 2001.
50. S. C. Manolagas, "From estrogen-centric to aging and oxidative stress: A revised perspective of the pathogenesis of osteoporosis," Endocrine Reviews, vol. 31, no. 3, pp. 266-300, 2010.
51. N. J. Simmonds, R. E. Allen, T. R. J. Stevens, R. N. M. Van Someren,D. R. Blake, andD. S. Rampton, "Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease," Gastroenterology, vol. 103, no. 1, pp. 186-196, 1992.
52. M. B. Grisham, R. P. MacDermott, and E. A. Deitch, "Oxidant defensemechanisms in the human colon," Inflammation, vol. 14, no. 6, pp. 669-680, 1990.
53. B. Sido, V. Hack, A. Hochlehnert, H. Lipps, C. Herfarth, and W. Dröge, "Impairment of intestinal glutathione synthesis in patients with inflammatory bowel disease," Gut, vol. 42, no. 4, pp. 485-492, 1998.
54. L. Lih-Brody, S. R. Powell, K. P. Collier et al., "Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease," Digestive Diseases and Sciences, vol. 41, no. 10, pp. 2078-2086, 1996.
55. M. B. Grisham, "Oxidants and free radicals in inflammatory bowel disease," The Lancet, vol. 344, no. 8926, pp. 859-861, 1994.
56. V. Gross, H. Arndt, T. Andus, K. D. Palitzsch, and J. Scholmerich, "Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications," Hepatogastroenterology, vol. 41, no. 4, pp. 320-327, 1994.
57. A. Banan, S. Choudhary, Y. Zhang, J. Z. Fields, and A. Keshavarzian, "Oxidant-induced intestinal barrier disruption and its prevention by growth factors in a human colonic cell line: role of the microtubule cytoskeleton," Free Radical Biology and Medicine, vol. 28, no. 5, pp. 727-738, 2000.
58. G. Bellomo, F. Mirabelli, M. Vairetti, F. Iosi, and W. Malorni, "Cytoskeleton as a target in menadione-induced oxidative stress in cultured mammalian cells. I. Biochemical and immunocytochemical features," Journal of Cellular Physiology, vol. 143, no. 1, pp. 118-128, 1990.
59. Y. Zhao and B. Zhao, "Oxidative stress and the pathogenesis of Alzheimer's disease," OxidativeMedicine and Cellular Longevity, vol. 2013, Article ID316523, 10 pages, 2013.
60. M. Sochocka, E. S. Koutsouraki, K. Gasiorowski, and J. Leszek, "Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: A new approach to therapy," CNS and Neurological Disorders-Drug Targets, vol. 12, no. 6, pp. 870-881, 2013.
61. M. A. Lovell,W. D. Ehmann, S. M. Butler, andW. R. Markesbery, "Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease," Neurology, vol. 45, no. 8, pp. 1594-1601, 1995.
62. M. A. Lovell, W. D. Ehmann, M. P. Mattson, and W. R. Markesbery, "Elevated 4-hydroxynonenal in ventricular fluid in Alzheimer's disease," Neurobiology of Aging, vol. 18, no. 5, pp. 457-461, 1997.
63. W. R. Markesbery and M. A. Lovell, "Four-hydroxynonenal, a product of lipid peroxidation, is increased in the brain in Alzheimer's disease," Neurobiology of Aging, vol. 19,no. 1, pp. 33-36, 1998.
64. K. S. Montine, E. Reich, M. D. Neely et al., "Distribution of reducible 4-hydroxynonenal adduct immunoreactivity in Alzheimer disease is associated with APOE genotype," Journal of Neuropathology & Experimental Neurology, vol. 57, no. 5, pp. 415-425, 1998.
65. L. T. McGrath, B. M. McGleenon, S. Brennan, D. McColl, S. McIlroy, and A. P. Passmore, "Increased oxidative stress in Alzheimer's disease as assessed with 4-hydroxynonenal but not malondialdehyde," QJM-Monthly Journal of the Association of Physicians, vol. 94, no. 9, pp. 485-490, 2001.
66. K. Hensley, N. Hall, R. Subramaniam et al., "Brain regional correspondence between Alzheimer's disease histopathology and biomarkers of protein oxidation," Journal of Neurochemistry, vol. 65, no. 5, pp. 2146-2156, 1995.
67. M. Y. Aksenov, M. V. Aksenova, D. A. Butterfield, J. W. Geddes, and W. R. Markesbery, "Protein oxidation in the brain in Alzheimer's disease," Neuroscience, vol. 103, no. 2, pp. 373-383, 2001.
68. M. Violet, L. Delattre, M. Tardivel et al., "A major role for Tau in neuronal DNA and RNA protection in vivo under physiological and hyperthermic conditions," Frontiers in Cellular Neuroscience, vol. 8, article 84, 2014.
69. M. A. Lovell, S. P. Gabbita, andW. R. Markesbery, "Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF," Journal of Neurochemistry, vol. 72, no. 2, pp. 771-776, 1999.
70. M. Ramamoorthy, P. Sykora, M. Scheibye-Knudsen et al., "Sporadic Alzheimer disease fibroblasts display an oxidative stress phenotype," Free Radical Biology andMedicine, vol. 53,no. 6, pp. 1371-1380, 2012.
71. M. Mórocz, J. Kálmán, A. Juhász et al., "Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease," Neurobiology of Aging, vol. 23, no. 1, pp. 47-53, 2002.
72. E. J. Mufson, E.-Y. Chen, E. J. Cochran, L. A. Beckett, D. A. Bennett, and J. H. Kordower, "Entorhinal cortex -amyloid load in individuals with mild cognitive impairment," Experimental Neurology, vol. 158, no. 2, pp. 469-490, 1999.
73. W. R. Markesbery, F. A. Schmitt, R. J. Kryscio, D. G. Davis, C. D. Smith, and D. R. Wekstein, "Neuropathologic substrate of mild cognitive impairment," Archives of Neurology, vol. 63, no. 1, pp. 38-46, 2006.
74. J. L. Price, D. W. McKeel Jr., V. D. Buckles et al., "Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease," Neurobiology of Aging, vol. 30, no. 7, pp. 1026-1036, 2009.
75. D. A. Butterfield, H. F. Poon, D. St Clair et al., "Redox proteomics identification of oxidatively modified hippocampal proteins in mild cognitive impairment: insights into the development of Alzheimer's disease," Neurobiology of Disease, vol. 22, no. 2, pp. 223-232, 2006.
76. J. N. Keller, F. A. Schmitt, S. W. Scheff et al., "Evidence of increased oxidative damage in subjects with mild cognitive impairment," Neurology, vol. 64, no. 7, pp. 1152-1156, 2005.
77. P. Rinaldi,M. C. Polidori, A. Metastasio et al., "Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease," Neurobiology of Aging, vol. 24, no. 7, pp. 915-919, 2003.
78. L. L. Torres, N. B. Quaglio, G. T. De Souza et al., "Peripheral oxidative stress biomarkers in mild cognitive impairment and Alzheimer's disease," Journal of Alzheimer's Disease, vol. 26, no. 1, pp. 59-68, 2011.
79. U. Püntener, S. G. Booth, V. H. Perry, and J. L. Teeling, "Longterm impact of systemic bacterial infection on the cerebral vasculature and microglia," Journal of Neuroinflammation, vol. 9, article 146, 2012.
80. Z. Wu, J. Zhang, and H. Nakanishi, "Leptomeningeal cells activate microglia and astrocytes to induce IL-10 production by releasing pro-inflammatory cytokines during systemic inflammation," Journal of Neuroimmunology, vol. 167, no. 1-2, pp. 90-98, 2005.
81. Z. Wu, Y. Hayashi, J. Zhang, and H. Nakanishi, "Involvement of prostaglandin E2 released from leptomeningeal cells in increased expression of transforming growth factor- in glial cells and cortical neurons during systemic inflammation," Journal ofNeuroscience Research, vol. 85,no. 1, pp. 184-192, 2007.
82. Z. Wu, L. Sun, S. Hashioka et al., "Differential pathways for interleukin-1 production activated by chromogranin A and amyloid in microglia," Neurobiology of Aging, vol. 34, no. 12, pp. 2715-2725, 2013.
83. Z. Wu, Y. Tokuda, X.-W. Zhang, and H. Nakanishi, "Agedependent responses of glial cells and leptomeninges during systemic inflammation," Neurobiology of Disease, vol. 32, no. 3, pp. 543-551, 2008.
84. X. Liu, Z. Wu, Y. Hayashi, and H. Nakanishi, "Age-dependent neuroinflammatory responses and deficits in long-term potentiation in the hippocampus during systemic inflammation," Neuroscience, vol. 216, pp. 133-142, 2012.
85. A. Gerhard, B. Neumaier, E. Elitok et al., "In vivo imaging of activated microglia using [11C]PK11195 and positron emission tomography in patients after ischemic stroke," NeuroReport, vol. 11, no. 13, pp. 2957-2960, 2000.
86. C. J. S. Price, D. Wang, D. K. Menon et al., "Intrinsic activated microglia map to the peri-infarct zone in the subacute phase of ischemic stroke," Stroke, vol. 37, no. 7, pp. 1749-1753, 2006.
87. L. Ruan, Z. Kang, G. Pei, and Y. Le, "Amyloid deposition and inflammation in APPswe/PS1dE9 mouse model of Alzheimer's disease," Current Alzheimer Research, vol. 6, no. 6, pp. 531-540, 2009.
88. E. Perry and M.-J. R. Howes, "Medicinal plants and dementia therapy: herbal hopes for brain aging" CNS Neuroscience & Therapeutics, vol. 17, no. 6, pp. 683-698, 2011.
89. V. S. Bankova, S. L. de Castro, and M. C. Marcucci, "Propolis: recent advances in chemistry and plant origin," Apidologie, vol. 31, no. 1, pp. 3-15, 2000.
90. M. C. Marcucci, "Propolis: chemical composition, biological properties and therapeutic activity," Apidologie, vol. 26, no. 2, pp. 83-99, 1995.
91. G. A. Burdock, "Review of the biological properties and toxicity of bee propolis (propolis)," Food and Chemical Toxicology, vol. 36, no. 4, pp. 347-363, 1998.
92. A. H. Banskota, Y. Tezuka, and S. Kadota, "Recent progress in pharmacological research of propolis," Phytotherapy Research, vol. 15, no. 7, pp. 561-571, 2001.
93. J. M. Sforcin, "Propolis and the immune system: A review," Journal of Ethnopharmacology, vol. 113, no. 1, pp. 1-14, 2007.
94. A. F. N. Ramos and J. L. Miranda, "Propolis: A review of its anti-inflammatory and healing actions," Journal of Venomous Animals and Toxins including Tropical Diseases, vol. 13, no. 4, pp. 697-710, 2007.
95. E. W. Englander, Z. Hu, A. Sharma, H.-M. Lee, Z.-H. Wu, and G. H. Greeley, "Rat MYH, a glycosylase for repair of oxidatively damaged DNA, has brain-specific isoforms that localize to neuronal mitochondria," Journal of Neurochemistry, vol. 83, no. 6, pp. 1471-1480, 2002.
96. J. M. Sforcin and V. Bankova, "Propolis: is there a potential for the development of new drugs?" The Journal of Ethnopharmacology, vol. 133, no. 2, pp. 253-260, 2011.
97. A. Q. Zhu, C. L. Masters, and Q. X. Li, "Tibet-medicine ratanasampil modulates amyloid precursor protein cleavage and C-terminal fragments (CTFS) in Tg2576 transgenic mice brain of Alzheimer's disease," Chinese Journal of Geriatric Dentistry, vol. 11, pp. 950-954, 2009.
98. A. Q. Zhu, Q. Xia, G. F. Li et al., "Ratanasampil (tibetan medicine, RNSP) reduces A-amyloid protein and proinflammatory factor levels and improves cognitive functions in mild-to-moderate Alzheimer's disease (AD) patients living at high altitude," Journal of Behavioral and Brain Science, vol. 2, pp. 82-91, 2012.
99. Y. Liu, Z. Wu, X. Zhang et al., "Leptomeningeal cells transduce peripheral macrophages inflammatory signal to microglia in reponse to Porphyromonas gingivalis LPS," Mediators of Inflammation, vol. 2013,Article ID 407562, 11 pages, 2013.
100. H. Sies, W. Stahl, and A. Sevanian, "Nutritional, dietary and postprandial oxidative stress," Journal of Nutrition, vol. 135, no. 5, pp. 96-972, 2005.
101. H. Sies, "Oxidative stress: A concept in redox biology and medicine," Redox Biology, vol. 4, pp. 180-183, 2015.
102. P. Mecocci,U. MacGarvey, andM. F. Beal, "Oxidative damage to mitochondrialDNAis increased inAlzheimer's disease," Annals of Neurology, vol. 36, no. 5, pp. 747-751, 1994.
103. P. Rinaldi, M. C. Polidori, A. Metastasio et al., "Plasma antioxidants are similarly depleted in mild cognitive impairment and in Alzheimer's disease," Neurobiology of Aging, vol. 24, no. 7, pp. 915-919, 2003.
104. P. Mecocci, E. Mariani, V. Cornacchiola, and M. C. Polidori, "Antioxidants for the treatment of mild cognitive impairment," Neurological Research, vol. 26, no. 5, pp. 598-602, 2004.
105. C. Lefebvre d'Hellencourt, C. N. Montero-Menei, R. Bernard, andD. Couez, "Vitamin D3 inhibits proinflammatory cytokines and nitric oxide production by the EOC13 microglial cell line," Journal of Neuroscience Research, vol. 71, no. 4, pp. 575-582, 2003.
106. Y. Li, L. Liu, S. W. Barger, R. E. Mrak, and W. S. T. Griffin, "Vitamin E suppression ofmicroglial activation is neuroprotective," Journal ofNeuroscience Research, vol. 66,no. 2, pp. 163-170, 2001.
107. J. P. Godbout, B. M. Berg, K. W. Kelley, and R. W. Johnson, "-tocopherol reduces lipopolysaccharide-induced peroxide radical formation and interleukin-6 secretion in primary murine microglia and in brain," Journal of Neuroimmunology, vol. 149, no. 1-2, pp. 101-109, 2004.
108. L. A. Bialowas-McGoey, A. Lesicka, and P. M. Whitaker-Azmitia, "Vitamin E increases S100b-mediated microglial activation in an S100b-overexpressing mousemodel of pathological aging," Glia, vol. 56, no. 16, pp. 1780-1790, 2008.
109. M. Djukic, M. L. Onken, S. Schütze et al., "VitaminDdeficiency reduces the immune response, phagocytosis rate, and intracellular killing rate of microglial cells," Infection and Immunity, vol. 82, no. 6, pp. 2585-2594, 2014.
110. E. Hjorth, M. Zhu, V. C. Toro et al., "Omega-3 fatty acids enhance phagocytosis of alzheimer's disease-related amyloid-42 by human microglia and decrease inflammatory markers," Journal of Alzheimer's Disease, vol. 35, no. 4, pp. 697-713, 2013.
111. S. Chen, H. Zhang, H. Pu et al., "n-3 PUFA supplementation benefits microglial responses to myelin pathology," Scientific Reports, vol. 4, article 7458, 2014.
112. R. M. Ortega, A. M. Requejo, A. M. López-Sobaler et al., "Cognitive function in elderly people is influenced by vitamin E status," The Journal of Nutrition, vol. 132, no. 7, pp. 2065-2068, 2002.
113. K. Murakami, N. Murata, Y. Ozawa et al., "Vitamin C restores behavioral deficits and amyloid- oligomerization without affecting plaque formation in a mouse model of alzheimer's disease," Journal of Alzheimer's Disease, vol. 26, no. 1, pp. 7-18, 2011.
114. L. An and T. Zhang, "Vitamins C and E reverse melamineinduced deficits in spatial cognition and hippocampal synaptic plasticity in rats," Neurotoxicology, vol. 44, pp. 132-139, 2014.
115. M. G. Isaac, R. Quinn, andN. Tabet, "Vitamin E for Alzheimer's disease and mild cognitive impairment," Cochrane Database Systematic Reviews, vol. 16, no. 3, Article IDCD002854, 2008.
116. J. C. Agnew-Blais, S. Wassertheil-Smoller, J. H. Kang et al., "Folate, vitamin B-6, and vitamin B-12 intake andmild cognitive impairment and probable dementia in the Women's Health Initiative Memory study," Journal of the Academy of Nutrition and Dietetics, vol. 115, no. 2, pp. 231-241, 2015.
117. A. M. Alavi Naeini, I. Elmadfa, A. Djazayery et al., "The effect of antioxidant vitamins E and C on cognitive performance of the elderly with mild cognitive impairment in Isfahan, Iran: A double-blind, randomized, placebo-controlled trial," European Journal of Nutrition, vol. 53, no. 5, pp. 1255-1262, 2014.
118. E. S. Abd Allah, A. M. Gomaa, and M. M. Sayed, "The effect of omega-3 on cognition in hypothyroid adult male rats," Acta Physiologica Hungarica, vol. 101, no. 3, pp. 362-376, 2014.
119. T. Cederholm, N. Salem Jr., and J. Palmblad, "-3 Fatty acids in the prevention of cognitive decline in humans," Advances in Nutrition, vol. 4, no. 6, pp. 672-676, 2013.